GLENMARK Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > glenmark

Technical Analysis

Technical Strength: 3.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 34.6. According to RSI analysis, glenmark is technically weak. 1.0 GLENMARK RSI Chart
MACD (?) MACD: -8.26 and Signal Line: -8.78. According to MACD analysis, glenmark is marginally strong. 7.0 GLENMARK MACD Chart
Simple Moving Average (?) According to simple moving average analysis, glenmark is in a strong downtrend. Major resistance levels are 301.09, 331.893, 497.7208. 0.0 GLENMARK Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, glenmark is in a strong downtrend. Major resistance levels are 305.734, 332.5847, 456.7584. 0.0 GLENMARK Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.275. 5.0 GLENMARK Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is below all levels. Resistance levels are 317.6927 and 332.425. Support level is 270.0. 2.5 GLENMARK Fibonacci Retracement Chart
Average True Range (?) ATR: 11.7 NA GLENMARK Average True Range Chart
Average Directional Index (?) ADX is 35.6 which means GLENMARK is in a trend. NA GLENMARK Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
November 11, 2019
Open Price 283.05
High Price 292.5
Low Price 281.45
Close Price 290.65
Absolute Change 4.2
Percentage Change 1.47%
Weekly Change -8.07%
Monthly Change 1.45%
Yearly Change -51.9%
52-week high 705.9
52-week low 270.0
Corporate Actions
ExDate Purpose
September 19, 2019 AGM/DIV-RS 2 PER SH
September 19, 2018 AGM/DIV-RS 2 PER SHARE
August 03, 2016 ANNUAL GENERAL MEETING
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.545
Confidence in Beta0.774%
Market Capital Rs. 7885.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 11 November 2019: Deliverable Quantity:2.55e+05 NA GLENMARK Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 11 November 2019: Daily Volatility:0.4451 NA GLENMARK Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 11 November 2019: PCR_OI:0.596 PCR:0.376 NA GLENMARK PCR Chart
Option Pain (?) 11 November 2019: Max Pain:300.0 NA GLENMARK Option Pain Chart
Premium (?) 11 November 2019 Premium: -0.25 Futures OI:6373000.0 NA GLENMARK Premium Chart
Option_MAX_OI (?) 11 November 2019: Price:290.65 Put with maximum OI:280.0 Call with maximum OI:320.0 NA GLENMARK Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
November 28, 2019 290.4 6373000.0 2122.0 2122.0 290.65
December 26, 2019 291.9 176000.0 60.0 60.0 290.65
January 30, 2020 290.3 5600.0 1.0 1.0 290.65

Announcements

October 01, 2018 Shareholders meeting Proceedings and Scrutinizer''s Report of the 40th Annual General Meeting {AGM) of Glenmark Pharmaceuticals Limited (''the Company'') held on September 28, 2018
August 13, 2018 News Clarification The Exchange has sought clarification from the Company with respect to news item captioned- True North in talks to buy into Glenmark API biz for Rs 1500 crIn this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
See all Announcements

Board Meetings

Date Meeting Date Purpose
November 06, 2019 November 14, 2019 Financial Results To consider and approve the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2019
August 01, 2019 August 13, 2019 Financial Results To consider and approve the financial results for the period ended Jun 30, 2019
See all Board Meetings

GLENMARK is part of...

Index Weightage
NFTYMCAP50 NA
CNXPHARMA NA

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play